Roland Barbante

Roland Barbante

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2025 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
ELEmilio Lozupone
Emilio Lozupone
RBRoland Barbante
Roland Barbante
GBGiovanni Barchetti
Giovanni Barchetti
MIMikel Terceño Izaga
Mikel Terceño Izaga
VVVictor Vazquez-Añón
Victor Vazquez-Añón
APAdriana Paladini
Adriana Paladini

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
RBRoland Barbante
Roland Barbante
SPSara Piciucchi
Sara Piciucchi
CRClaudia Ravaglia
Claudia Ravaglia
AVAntonio Vizzuso
Antonio Vizzuso
EGEmanuela Giampalma
Emanuela Giampalma
VPVenerino Poletti
Venerino Poletti
Patients diagnosed with pulmonary cGVHD between 2010 and 2023 were included in this observational retrospective study. Inclusion criteria were: age above 18, and available CT scan at diagnosis of cGVHD of the lung. Hematological history, treatment, transplant time, and symptoms were recorded. CT scans were evaluated by two Radiologists and findings classified according the Glossary of Fleischner society. cGVHD presented with three main patterns: acute/subacute lung injury, bronchiolar pattern, and restrictive pattern with pleuroparenchymal fibroelastosis (PPFE). Acute/subacute lung injury group (n=5) exhibited features such as ground glass, crazy paving, reverse halo sign, and perilobular pattern. Bronchiolar presentation (n=20) ranged from centrilobular nodules to extensive mosaic attenuation. Restrictive phenotype was mainly standalone PPFE or PPFE with signs of airways disease (n=12) and fibrotic interstitial lung disease (n=2 definite UIP; n=1 probable UIP). Onset occurred around 15 months, 3 years, and later, respectively. This study highlights CT's role in defining cGVHD's clinical-radiological phenotypes. Different patterns are associated with diverse onset times.